Morepen Laboratories Limited · NSE:MOREPENLAB
Morepen Laboratories — Q3 FY2019 Earnings Presentation
12 slides from Morepen Laboratories's earnings presentation, Feb 4, 2019
Slide 1: Covering letter to NSE and BSE
.... ... .. ....:~ ~ i\\O~EPEN Date: 04/01/2019 To, The National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai- 400 051 Dalal Street, Mumbai- 400 001 Tel No: (022) 26598100- 8114 Phones: 91-22-22721233/4 Fax No: (022)
Slide 2: Investors Presentation (Q3) February 2019
“ I CHOOSE INVESTORS PRESENTATION (Q3) February 2019
Slide 3: Disclaimer
Disclaimer: This presentation has been prepared by Morepen Laboratories Limited (“Company”) solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation contains expressed or implied forward looking
Slide 4: Synopsis of Q3'FY19 Performance
Synopsis of Q3’FY19 Performance ₹ crores Consolidated Consolidated Y-o-Y Q3’FY19 Q3’FY18 Growth Net Revenue 214.58 155.89 37.6% Expenditure 195.32 136.84 42.8% EBIDTA 19.27 19.06 1.1% Interest 0.43 0.91 (53.4%) Cash Surplus 18.84 18.15 3.9% Dep. & Amortization 9.80 7.70 27.2% Income Tax (0.13) (0.01
Slide 5: Highlights of Q3'FY19 Performance
Highlights of Q3’FY19 Performance ₹ crores • Net Revenue up by 38% at Rs. 214.58 crore backed by improved sales revenue from API and Home Diagnostics . Export sales up by 83 % at Rs. 96.56 crore • Montelukast sales have grown by 60%; Export turnover jumps by 213%. Loratadine recorded remarkable grow
Slide 6: Segments wise growth
Segments wise growth ₹ crores • Overall business for the Quarter (Q3’FY19) has grown at 38% as compared to 215 Q3’FY18 • API Export has shown extremely good results having grown at 84% for the 38% Q3’FY19. Total API business contributed 58% to the quarterly sales. • Home Diagnostic Devices business
Slide 7: API: Increasing Export Business
API: Increasing Export Business ₹ crores • API Export has got a jump of 84% during the Q3’FY19 as compared to Q3’FY18 while total API business has grown by 50% API Sales 120.2 • Loratadine sales has grown by 64% in Q3’FY19 on Y-to-Y basis. Export of Loratadine has gone up by 54% this quarter Q3’FY19
Slide 8: Growing Branded Portfolio
Growing Branded Portfolio: ₹ crores • Dr. Morepen brand basket has grown from Rs. 74.30 crores to Rs. 89.03 crores for the Q3’FY19 and has registered an upside of 20% as compared Q3’FY18 • Within the basket, Diagnostic Devices business has registered a growth of 53% while Finished Dosages has regist
Slide 9: Devices Business - Growth Driver
Devices Business - Growth Driver ₹ crores • Home Devices portfolio has been growing with fast pace and has recorded a growth of 53% during the quarter. 42.4 • Blood Glucose Monitors have marked a growth of 77% in Q3’FY19 as against 53% Q3’FY18. Total Gluco monitors installed during Q3’FY19 were doub
Slide 10: Finished Dosages
Finished Dosages: ₹ crores • Finished Dosages has reported slight increase of 0.6% in Q3FY’19 as compared to 32.22 last year same quarter. • Branded Prescription (Rx) products has grown by 15% during the Q3’FY’19 32.03 • Good growth is seen in Antibiotics (45%) products and Gastrointestinal(10%) • B
Slide 11: OTC Business
OTC Business: ₹ crores • Total OTC category has registered a slight decline of 0.8% during the quarter. • Lemolate Sales have gone up strongly by 14% during the Q3’FY19 on Y-to-Y basis 1453 1442 • Other small brands which are distribution and reach based have declined by 22% in the Q3’FY19. • The co
Slide 12: Thank You
Thank Vfeu gt MOREPEN ‘The Joy Of Growing Together
Morepen Laboratories — Q3 FY2019 Earnings Presentation on 6ix